- Home
- EHI vs ESPR Comparison
EHI vs ESPR Comparison
Compare EHI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHI
- ESPR
- Stock Information
- Founded
- EHI 2003
- ESPR 2008
- Country
- EHI United States
- ESPR United States
- Employees
- EHI N/A
- ESPR N/A
- Industry
- EHI Investment Managers
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- EHI Finance
- ESPR Health Care
- Exchange
- EHI Nasdaq
- ESPR Nasdaq
- Market Cap
- EHI 194.8M
- ESPR 202.2M
- IPO Year
- EHI N/A
- ESPR 2013
- Fundamental
- Price
- EHI $6.49
- ESPR $1.20
- Analyst Decision
- EHI
- ESPR Buy
- Analyst Count
- EHI 0
- ESPR 6
- Target Price
- EHI N/A
- ESPR $6.50
- AVG Volume (30 Days)
- EHI 44.5K
- ESPR 3.1M
- Earning Date
- EHI 01-01-0001
- ESPR 08-11-2025
- Dividend Yield
- EHI 11.54%
- ESPR N/A
- EPS Growth
- EHI N/A
- ESPR N/A
- EPS
- EHI N/A
- ESPR N/A
- Revenue
- EHI N/A
- ESPR $259,574,000.00
- Revenue This Year
- EHI N/A
- ESPR $4.07
- Revenue Next Year
- EHI N/A
- ESPR N/A
- P/E Ratio
- EHI N/A
- ESPR N/A
- Revenue Growth
- EHI N/A
- ESPR 12.99
- 52 Week Low
- EHI $6.00
- ESPR $0.69
- 52 Week High
- EHI $7.75
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- EHI 51.62
- ESPR 63.86
- Support Level
- EHI $6.49
- ESPR $1.10
- Resistance Level
- EHI $6.58
- ESPR $1.26
- Average True Range (ATR)
- EHI 0.05
- ESPR 0.08
- MACD
- EHI -0.00
- ESPR 0.02
- Stochastic Oscillator
- EHI 54.70
- ESPR 93.55
About EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Energy, Healthcare, Industrials, materials, and others.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.